Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma

We have previously shown that disruption of promyelocytic leukemia nuclear bodies (PML NBs) is sufficient to activate the EBV lytic cycle thus making infected cells susceptible to ganciclovir (GCV) mediated killing in vitro. Here we show that co-administration of GCV and arsenic trioxide (ATO), a PM...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sides, Mark D, Sosulski, Meredith L, Luo, Fayong, Lin, Zhen, Flemington, Erik K, Lasky, Joseph A
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3666899/
https://ncbi.nlm.nih.gov/pubmed/23680002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1743-422X-10-152
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados